Predictions
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€466.50
06.06.23
06.06.23
€600.00
06.06.24
06.06.24
4.81%
12:12
12:12
Leading role in innovation
Could be worthwhile Investment >10% per year
Some uniques
Small Risks for its business
Universal Health Services B
Start price
Target price
Perf. (%)
€127.00
02.06.23
02.06.23
€151.62
02.06.24
02.06.24
31.14%
22.05.24
22.05.24
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€307.95
30.05.23
30.05.23
€356.18
30.05.24
30.05.24
34.45%
10:56
10:56
Universal Health Services B
Start price
Target price
Perf. (%)
€119.00
26.05.23
26.05.23
-
26.05.24
26.05.24
42.64%
22.05.24
22.05.24
Agilent Technologies Inc.
Start price
Target price
Perf. (%)
€106.30
24.05.23
24.05.23
€148.51
24.05.24
24.05.24
33.43%
09:47
09:47
Agilent Technologies Inc.
Start price
Target price
Perf. (%)
€106.30
24.05.23
24.05.23
€148.51
24.05.24
24.05.24
33.43%
09:47
09:47
Agilent Technologies Inc.
Start price
Target price
Perf. (%)
€106.30
24.05.23
24.05.23
€133.66
24.05.24
24.05.24
33.43%
09:47
09:47
Agilent Technologies Inc.
Start price
Target price
Perf. (%)
€106.30
24.05.23
24.05.23
€133.66
24.05.24
24.05.24
33.43%
09:47
09:47
Agilent Technologies Inc.
Start price
Target price
Perf. (%)
€106.30
24.05.23
24.05.23
€116.95
24.05.24
24.05.24
33.43%
09:47
09:47
Agilent Technologies Inc.
Start price
Target price
Perf. (%)
€106.30
24.05.23
24.05.23
€134.59
24.05.24
24.05.24
33.43%
09:47
09:47
Agilent Technologies Inc.
Start price
Target price
Perf. (%)
€106.30
24.05.23
24.05.23
€134.59
24.05.24
24.05.24
33.43%
09:47
09:47
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€196.52
08.01.22
08.01.22
€915.00
14.01.27
14.01.27
110.69%
10:56
10:56
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
ROE higher than 15% per year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.48
30.09.16
30.09.16
€98.00
08.09.26
08.09.26
12.50%
12:50
12:50
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued